Pfizer Global Research and Development

Summary

Organization: Pfizer Global Research and Development
Country: USA

Top Publications

  1. doi Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers
    John Davis
    Research Clinical Pharmacology, Pfizer Inc, Sandwich, Kent, United Kingdom
    Clin Ther 32:1889-95. 2010
  2. ncbi The early effects of short-term dexamethasone administration on hepatic and serum alanine aminotransferase in the rat
    Elisa R Jackson
    Portfolio and Project Management Project Planning, Pfizer Inc Pfizer Global Research and Development, New London, Connecticut 06320, USA
    Drug Chem Toxicol 31:427-45. 2008
  3. doi Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery
    Jim Jiao
    Pfizer Global Research and Development, Pfizer Inc, Eastern Point Road, Groton, CT 06340, USA
    Adv Drug Deliv Rev 60:1663-73. 2008
  4. doi Homo-timeric structural model of human microsomal prostaglandin E synthase-1 and characterization of its substrate/inhibitor binding interactions
    Li Xing
    Department of Structural and Computational Chemistry, St Louis Laboratories, Pfizer Inc, 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
    J Comput Aided Mol Des 23:13-24. 2009
  5. doi Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys
    Chandra Prakash
    Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Groton, CT 06340, USA
    Drug Metab Dispos 36:1753-69. 2008
  6. ncbi Development of a self-emulsifying formulation that reduces the food effect for torcetrapib
    M E Perlman
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Int J Pharm 351:15-22. 2008
  7. ncbi Prevalence of storage and voiding symptoms among men aged 40 years and older in a US population-based study: results from the Male Attitudes Regarding Sexual Health study
    D B Glasser
    Pfizer Inc, New York, NY 10017, USA
    Int J Clin Pract 61:1294-300. 2007
  8. ncbi The impact of targeted training, a dedicated protocol and on-site training material in reducing observer variability of prostate and transition zone dimensions measured by transrectal ultrasonography, in multicentre multinational clinical trials of men wi
    Philip S Murphy
    Pfizer Global Research and Development, Sandwich, Kent, UK
    BJU Int 100:102-6. 2007
  9. ncbi A high performance liquid chromatography assay for monitoring proprotein convertase activity
    Troii Hall
    Pfizer Inc, 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
    J Chromatogr A 1148:46-54. 2007
  10. ncbi Commentary on AAPS Workshop: dissolution testing for the twenty-first century: linking critical quality attributes and critical process parameters to clinically relevant dissolution
    Cheng Tong
    Pfizer Global Research and Development, Pfizer, Inc, Eastern Point Road, Groton, CT 06340, USA
    Pharm Res 24:1603-7. 2007

Detail Information

Publications62

  1. doi Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers
    John Davis
    Research Clinical Pharmacology, Pfizer Inc, Sandwich, Kent, United Kingdom
    Clin Ther 32:1889-95. 2010
    ..Lersivirine is a nonnucleoside reverse transcriptase inhibitor undergoing clinical development for the treatment of HIV-1...
  2. ncbi The early effects of short-term dexamethasone administration on hepatic and serum alanine aminotransferase in the rat
    Elisa R Jackson
    Portfolio and Project Management Project Planning, Pfizer Inc Pfizer Global Research and Development, New London, Connecticut 06320, USA
    Drug Chem Toxicol 31:427-45. 2008
    ..However, early DEXA treatment did correlate with apparent ALT induction. Ultimately, this may explain some early asymptomatic serum ALT elevations seen clinically...
  3. doi Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery
    Jim Jiao
    Pfizer Global Research and Development, Pfizer Inc, Eastern Point Road, Groton, CT 06340, USA
    Adv Drug Deliv Rev 60:1663-73. 2008
    ....
  4. doi Homo-timeric structural model of human microsomal prostaglandin E synthase-1 and characterization of its substrate/inhibitor binding interactions
    Li Xing
    Department of Structural and Computational Chemistry, St Louis Laboratories, Pfizer Inc, 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
    J Comput Aided Mol Des 23:13-24. 2009
    ..The structural model that we have derived could serve as a useful tool for structure-guided design of inhibitors for this emergently important therapeutic target...
  5. doi Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys
    Chandra Prakash
    Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Groton, CT 06340, USA
    Drug Metab Dispos 36:1753-69. 2008
    ..The catechol (M21) and its sulfate conjugate (M10) were observed only in monkeys, whereas the glucuronide conjugate of the methylated catechol (M8) and hydroxy-LAS (M9) were detected only in rats...
  6. ncbi Development of a self-emulsifying formulation that reduces the food effect for torcetrapib
    M E Perlman
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Int J Pharm 351:15-22. 2008
    ..Studies of in vitro lipolysis are being conducted to aid in understanding the in vitro/in vivo relationships for torcetrapib SEDDS absorption...
  7. ncbi Prevalence of storage and voiding symptoms among men aged 40 years and older in a US population-based study: results from the Male Attitudes Regarding Sexual Health study
    D B Glasser
    Pfizer Inc, New York, NY 10017, USA
    Int J Clin Pract 61:1294-300. 2007
    ..Lower urinary tract symptoms (LUTS) are categorised as storage (urgency, frequency, nocturia and incontinence), voiding (sensation of incomplete emptying, hesitancy, weak stream and straining) or mixed symptoms...
  8. ncbi The impact of targeted training, a dedicated protocol and on-site training material in reducing observer variability of prostate and transition zone dimensions measured by transrectal ultrasonography, in multicentre multinational clinical trials of men wi
    Philip S Murphy
    Pfizer Global Research and Development, Sandwich, Kent, UK
    BJU Int 100:102-6. 2007
    ....
  9. ncbi A high performance liquid chromatography assay for monitoring proprotein convertase activity
    Troii Hall
    Pfizer Inc, 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
    J Chromatogr A 1148:46-54. 2007
    ..In addition, inhibition curves were plotted and IC(50) values calculated for PACE-4 and furin in the presence of two polyarginine peptides, hexa and deca-D-arginine...
  10. ncbi Commentary on AAPS Workshop: dissolution testing for the twenty-first century: linking critical quality attributes and critical process parameters to clinically relevant dissolution
    Cheng Tong
    Pfizer Global Research and Development, Pfizer, Inc, Eastern Point Road, Groton, CT 06340, USA
    Pharm Res 24:1603-7. 2007
    ..Views expressed in this report are those of the authors and do not necessarily reflect those of the FDA and USP...
  11. ncbi A two-stage phase II trial design utilizing both primary and secondary endpoints
    Xun Lin
    Pfizer Global Research and Development, La Jolla Laboratories, 10555 Science Center Drive, San Diego, CA 92121, USA
    Pharm Stat 7:88-92. 2008
    ..The family-wise Type 1 error rate and statistical power of the proposed design are investigated under a variety of situations by means of Monte-Carlo simulations...
  12. ncbi Impact of denaturation with urea on recombinant apolipoprotein A-IMilano ion-exchange adsorption: equilibrium uptake behavior and protein mass transfer kinetics
    Alan K Hunter
    Pfizer Inc, Global Biologics, Chesterfield, MO, USA
    Biotechnol J 2:110-20. 2007
    ..Based on light-scattering data reported for apo A-I, protein self association appears to be the dominant cause of slow protein mass transfer observed under non-denaturing conditions...
  13. ncbi Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects
    Karen L Houseknecht
    Department of Cardiovascular, Metabolic and Endocrine Diseases, Pfizer Global Research and Development, Groton, CT 06340, USA
    Neuropsychopharmacology 32:289-97. 2007
    ..OLAN and CLOZ can thus rapidly induce marked insulin resistance, which could contribute to the hyperglycemia and ketoacidosis reported for patients receiving those therapies...
  14. ncbi Designing better drugs: predicting cytochrome P450 metabolism
    Marcel J de Groot
    Sandwich Chemistry, Pfizer Global Research and Development, Sandwich Laboratories, Kent CT13 9NJ, UK
    Drug Discov Today 11:601-6. 2006
    ..These models help to explain and, more importantly, predict the involvement of P450s in the metabolism of specific compounds and guide the drug-design process...
  15. ncbi In vitro cytochrome P450 inhibition and induction
    Robert L Walsky
    Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA
    Curr Drug Metab 9:928-39. 2008
    ....
  16. pmc Origins, actions and dynamic expression patterns of the neuropeptide VGF in rat peripheral and central sensory neurones following peripheral nerve injury
    Andrew Moss
    UCL Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK
    Mol Pain 4:62. 2008
    ....
  17. ncbi Notch signalling in cancer stem cells
    V Bolós
    Medical Oncology Department, Pfizer Spain, Alcobendas, Madrid, Spain
    Clin Transl Oncol 11:11-9. 2009
    ..Additionally, we will pay attention to their role in adult stem cell self-renewal, and cell fate specification and differentiation, and we will also review evidence that supports their implication in cancer...
  18. doi Supercritical fluid chromatography and steady-state recycling: phase appropriate technologies for the resolutions of pharmaceutical intermediates in the early drug development stage
    Tony Q Yan
    Analytical Chemistry and Sample Logistics, Antibacterial Medicinal Chemistry, Pfizer Global R and D, Pfizer, Groton, Connecticut 06340, USA
    Chirality 22:922-8. 2010
    ..From the separation results of these purifications, SFC and SSR are clearly phase appropriate technologies in the early drug development stage...
  19. doi Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6
    Jill E Chrencik
    Pfizer Inc 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
    J Mol Biol 400:413-33. 2010
    ....
  20. doi Understanding the clinical pharmacokinetics of a GABAA partial agonist by application of in vitro tools
    Aarti D Sawant
    Department of Pharmacokinetics, Pharmacodynamics and Metabolism, Pfizer Global Research and Development, Groton New London Laboratories, Pfizer Inc, Groton, CT 06340, USA
    Xenobiotica 40:476-84. 2010
    ....
  21. doi PF-03475952: a potent and neutralizing fully human anti-CD44 antibody for therapeutic applications in inflammatory diseases
    Herbert A Runnels
    Pfizer Global Research and Development, St Louis Laboratories, Chesterfield, MO 63017, USA
    Adv Ther 27:168-80. 2010
    ..CD44-deficient mice exhibit decreased disease in a mouse arthritis model...
  22. doi Comparison between recombinant P450s and human liver microsomes in the determination of cytochrome P450 Michaelis-Menten constants
    K Youdim
    Pfizer, PDM, Sandwich, UK
    Xenobiotica 40:235-44. 2010
    ..Estimation of these parameters during early discovery will aid in the understanding of dosages at which non-linearity may occur, but potentially aid predictions of likely clinical drug-drug interactions...
  23. pmc Integrated risk assessment and predictive value to humans of non-clinical repolarization assays
    Robert M Wallis
    Pfizer, Groton, CT 06340, USA
    Br J Pharmacol 159:115-21. 2010
    ....
  24. doi Structural and biophysical characterization of XIAP BIR3 G306E mutant: insights in protein dynamics and application for fragment-based drug design
    Cathy D Moore
    Department of Chemistry, Pfizer Global Research and Development, La Jolla Laboratories, San Diego, CA 92121, USA
    Chem Biol Drug Des 74:212-23. 2009
    ..The presented data outline a protein engineering strategy that allowed mapping of AV-replacements with better sensitivity and precision...
  25. doi Synthesis and SAR studies of 1,4-diazabicyclo[3.2.2]nonane phenyl carbamates--subtype selective, high affinity alpha7 nicotinic acetylcholine receptor agonists
    Christopher J O'Donnell
    Neuroscience Medicinal Chemistry, Pfizer Global Research and Development, Groton, CT 06340, United States
    Bioorg Med Chem Lett 19:4747-51. 2009
    ....
  26. doi Can light absorption and photostability data be used to assess the photosafety risks in patients for a new drug molecule?
    Brian Henry
    Pharmaceutical Sciences, Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, UK
    J Photochem Photobiol B 96:57-62. 2009
    ..Molecules with an MEC less than 1000 L mol(-1)cm(-1)are deemed less of a photosafety risk since this low level of light absorption is unlikely to prove harmful...
  27. doi Effect of compound plate composition on measurement of hERG current IC(50) using PatchXpress
    Zun Li Mo
    Pfizer Global Research and Development, Drug Safety Research and Development, Chesterfield, MO 63017, USA
    J Pharmacol Toxicol Methods 60:39-44. 2009
    ....
  28. doi Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial
    Douglas Feltner
    Pfizer Global Research and Development, MS 6025 B2234, New London, CT 06320, USA
    J Psychiatr Res 43:1224-30. 2009
    ..Excluding these 56 patients from the analysis resulted in a greater separation of active treatment from placebo. The PRSS is a promising tool for predicting placebo response in clinical trials and requires further use and validation...
  29. doi Design, synthesis, and pharmacology of fluorescently labeled analogs of serotonin: application to screening of the 5-HT2C receptor
    Peter Cornelius
    Department of Cardiovascular, Metabolic, and Endocrine Diseases, Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    J Biomol Screen 14:360-70. 2009
    ..A 384-well-based high-throughput assay that is rapid, economical, and predictive of test compounds' ability to bind to the 5-HT2C receptor has been compiled and validated...
  30. ncbi 'Muscle-sparing' statins: preclinical profiles and future clinical use
    Jeffrey A Pfefferkorn
    Pfizer Global Research and Development, Cardiovascular and Metabolic Disease Chemistry, Eastern Point Road, Groton, CT 06340, USA
    Curr Opin Investig Drugs 10:245-52. 2009
    ..In this review, the preclinical and early clinical data for these next generation statins are discussed...
  31. ncbi Using a tritiated compound to elucidate its preclinical metabolic and excretory pathways in vivo: exploring tritium exchange risk
    Christopher L Shaffer
    Department of Pharmacokinetics, Pharmacodynamics and Metabolism, Pfizer Global Research and Development, Pfizer Inc, Groton, CT 06340, USA
    Drug Metab Dispos 34:1615-23. 2006
    ....
  32. ncbi Use of nano-electrospray for metabolite identification and quantitative absorption, distribution, metabolism and excretion studies
    Cornelis E C A Hop
    Pfizer Global Research and Development, Department of Pharmacokinetics, Dynamics and Metabolism, Eastern Point Road, Groton, CT 06340, USA
    Curr Drug Metab 7:557-63. 2006
    ..The use of these devices for the determination of pharmacokinetics and metabolite identification will be described and particular attention will be paid to the distinct advantages and disadvantages these devices offer...
  33. ncbi Cardiology patient page. Angiotensin receptor blockers
    Steven G Terra
    PharmD, Pfizer Global Research and Development, 445 Eastern Point Rd, MS 8260 2505, Groton, Conn 06340, USA
    Circulation 107:e215-6. 2003
  34. ncbi Cyclization of N-terminal S-carbamoylmethylcysteine causing loss of 17 Da from peptides and extra peaks in peptide maps
    Kieran F Geoghegan
    Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, USA
    J Proteome Res 1:181-7. 2002
    ..1 M NH4HCO3 at 37 degrees C, with the half-life of the acyclic form being 10-12 h for several peptides tested. This is similar to the rate at which N-terminal pyroglutamate forms from N-terminal glutamine...
  35. ncbi Microsomal triglyceride transfer protein (MTP) inhibitors: discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms
    George Chang
    Departments of Metabolic Diseases and Medicinal Chemistry, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA
    Curr Opin Drug Discov Devel 5:562-70. 2002
    ..Finding a degree of efficacy that can be safely tolerated defines the dilemma surrounding the advancement of these compounds to clinical practice...
  36. ncbi A novel antibiotic CJ-17,572 from a fungus, Pezicula sp
    Yutaka Sugie
    Exploratory Medicinal Sciences, PGRD, Nagoya Laboratories, Pfizer Pharmaceuticals, Inc, Aichi, Japan
    J Antibiot (Tokyo) 55:19-24. 2002
    ..The compound inhibits the growth of multi-drug resistant Staphylococcus aureus and Enterococcusfaecalis with IC50s of 10 and 20 microg/ml, respectively...
  37. ncbi Identification of a second binding site in the estrogen receptor
    Willem P van Hoorn
    Department of Molecular Informatics, Structure and Design, Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
    J Med Chem 45:584-9. 2002
    ..Most likely, the smaller steroid binding site of ER beta compared to ER alpha and/or the apparent larger flexibility of helix 12 of ER beta make ER beta more readily adopt an antagonist conformation...
  38. ncbi Drug screening of pharmaceutical discovery compounds by micro-size exclusion chromatography/mass spectrometry
    Paul A Wabnitz
    Department of Pharmacokinetics, Dynamics and Metabolism Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Rapid Commun Mass Spectrom 16:85-91. 2002
    ....
  39. ncbi Dissolution behavior of porcine somatotropin with simultaneous gel formation and lysine Schiff-base hydrolysis
    C J Roberts
    Department of Pharmaceutical R and D, MS 8156 16, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA
    J Control Release 77:107-16. 2001
    ....
  40. ncbi Liquid chromatography-tandem mass spectrometric quantitation of cyclophosphamide and its hydroxy metabolite in plasma and tissue for determination of tissue distribution
    N Sadagopan
    Pharmacokinetics, Dynamics, and Metabolism Department, Pfizer Global Research, Ann Arbor, MI 48105, USA
    J Chromatogr B Biomed Sci Appl 759:277-84. 2001
    ..The CP and oxime plasma levels correlated well with dose amounts. The CP levels in the spleen and plasma were similar while the oxime levels in the spleen were significantly lower than the plasma...
  41. ncbi Biotransformation of selamectin with Streptomyces lydicus SX-1298 using a novel static agar fermentation system with Reemay mesh
    M S Pacey
    Veterinary Medicine Discovery, Pfizer Global Research and Development, Sandwich, Kent, UK
    J Antibiot (Tokyo) 54:448-54. 2001
    ..Using this approach with a newly isolated biotransforming organism, Streptomyces lydicus SX1298, a series of hydroxylations and an O-demethylation is described for selamectin the first endectocide for cats and dogs...
  42. ncbi 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters
    S E Hagen
    Department of Chemistry, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    J Med Chem 44:2319-32. 2001
    ..This thiophene derivative also exhibited excellent antiviral efficacy against mutant HIV protease and resistant HIV strains. For these reasons, compound 13-(S) was chosen for further preclinical evaluation...
  43. ncbi The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression
    T M Bocan
    Department of Cardiovascular Therapeutics, Pfizer Global Research and Development, Ann Arbor Laboratories, Pfizer Inc, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Atherosclerosis 157:97-105. 2001
    ....
  44. pmc Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice
    M J Callahan
    Neuroscience Therapeutics, Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Rd, Ann Arbor, MI 48105, USA
    Am J Pathol 158:1173-7. 2001
    ..These data show that senescent female Tg2576 mice deposit more amyloid in the brain than do male mice, and may provide an animal model in which the influence of sex differences on cerebral amyloid pathology can be evaluated...
  45. ncbi Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents
    T Burt
    Medical Director, Depression Anxiety Worldwide Team, Pfizer Inc 235 East 42nd Street, 235 10 29, New York, NY 10023, USA
    Curr Psychiatry Rep 2:473-8. 2000
    ....
  46. ncbi Abnormal phospholipid composition impairs HDL biogenesis and maturation in mice lacking Abca1
    Omar L Francone
    Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    Biochemistry 42:8569-78. 2003
    ..Taken together, these observations suggest that ABCA1 is necessary for the adequate lipidation of apoAI, which enables the interaction with LCAT and subsequent maturation...
  47. pmc Efficacy of single-dose azithromycin in treatment of acute otitis media in children after a baseline tympanocentesis
    Michael W Dunne
    Pfizer Global Research and Development, New London, Connecticut 06320, USA
    Antimicrob Agents Chemother 47:2663-5. 2003
    ..Clinical cure rates for patients infected with Streptococcus pneumoniae (67 of 76; 88%) and Haemophilus influenzae (28 of 44; 64%) were consistent with historical rates for the 5-day dosing regimen...
  48. ncbi Discovery of novel benzothiazolesulfonamides as potent inhibitors of HIV-1 protease
    Srinivasan R Nagarajan
    Pfizer Global Research and Development, Pfizer Inc, 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
    Bioorg Med Chem 11:4769-77. 2003
    ..During the course of our studies, we also developed an efficient synthesis of benzothiazole-6-sulfonic acid via a two-step procedure starting from sulfanilamide...
  49. ncbi Comparison of skin esterase activities from different species
    Jeffery J Prusakiewicz
    Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, 2800 Plymouth Rd, Ann Arbor, Michigan 48105, USA
    Pharm Res 23:1517-24. 2006
    ..The aims of this study were to evaluate the suitability of minipig and rat skin as in vitro models of human epidermal esterase activity...
  50. ncbi Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function
    Judith A Siuciak
    CNS Discovery, Pfizer Global Research and Development, MS 8220 4138 Eastern Point Road, Groton, CT 06340, USA
    Neuropharmacology 51:374-85. 2006
    ..These results are discussed in relationship to the hypothesis that PDE10A inhibition presents a novel treatment for psychosis...
  51. ncbi N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor
    M Jonathan Fray
    Sandwich Chemistry, Pfizer Global Research and Development, Sandwich, UK
    Bioorg Med Chem Lett 16:4345-8. 2006
    ..Two compounds possessed comparable in vitro profiles to the dual reuptake inhibitor duloxetine...
  52. ncbi Targeting virulence for antibacterial chemotherapy: identifying and characterising virulence factors for lead discovery
    Andrea Marra
    Pfizer Inc, Groton, Connecticut 06340, USA
    Drugs R D 7:1-16. 2006
    ....
  53. ncbi QT interval prolongation: and the beat goes on
    Mehran Jalaie
    Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Mini Rev Med Chem 5:1083-91. 2005
    ..Lastly, the strengths and weaknesses of each modeling method is presented along with insight to the appropriate use of each model...
  54. ncbi Risk identification and management: MRI as a research tool in toxicology studies of new chemical entities
    Mark W Tengowski
    Pfizer Global Research and Development, Pfizer, Inc, 12800 Plymouth Road 16 1A 6, Ann Arbor, MI 48105, USA
    Prog Drug Res 62:257-78. 2005
  55. ncbi A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia
    Hua Zhu Ke
    Osteoporosis Research, Pfizer Global Research and Development, Groton Laboratories, Groton, Connecticut 06340, USA
    J Bone Miner Res 20:1742-55. 2005
    ....
  56. ncbi Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance
    Robin P Hertz
    US Outcomes Research Population Studies, Pfizer Global Pharmaceuticals, Pfizer Inc, New York, NY 10017, USA
    Clin Ther 27:1064-73. 2005
    ....
  57. ncbi The plasmodial apicoplast was retained under evolutionary selective pressure to assuage blood stage oxidative stress
    Steven Toler
    Pfizer Inc, Clinical Pharmacology, 50 Pequot Avenue, B3227, New London, CT 06320, USA
    Med Hypotheses 65:683-90. 2005
    ....
  58. ncbi [Drug added therapeutic value: what is it, how is it assessed and what should be it's role in pharmaceutical policy?]
    J Soto Alvarez
    Departamento de Farmacoepidemiología y Farmacoeconomía, Unidad Médica, Pfizer S A, Alcobendas, Madrid
    An Med Interna 22:39-42. 2005
  59. ncbi Metabonomics in toxicology: a review
    Donald G Robertson
    Metabonomics Evaluation Group, Department of World Wide Safety Sciences, Pfizer Global Research and Development, Ann Arbor, Michigan 48105, USA
    Toxicol Sci 85:809-22. 2005
    ..The jargon, logistics, and applications of the technology are covered in some detail with emphasis on recent work in the field...
  60. ncbi Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors
    Oday Hamid
    Pfizer Global Research and Development, Ann Arbor Laboratory, Ann Arbor, Mich 48105, USA
    J Am Pharm Assoc (2003) 44:52-8. 2004
    ..To describe the role of tyrosine kinase (TK) and its subreceptors in the development of cancer and the role of TK inhibitors in cancer treatment...
  61. ncbi Potent inhibition of human liver aldehyde oxidase by raloxifene
    R Scott Obach
    Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Global Research and Development, Groton Laboratories, Groton, CT 06340, USA
    Drug Metab Dispos 32:89-97. 2004
    ....
  62. ncbi Pharmacokinetics and metabolism in early drug discovery
    D A Smith
    Pfizer Central Research, Department of Drug Metabolism, Sandwich, Kent, CT13 9NJ, UK
    Curr Opin Chem Biol 3:373-8. 1999
    ..Through linking of in silico and in vitro methods, considerable progress has recently been made towards this future perspective. Despite this progress, these approaches do not yet replace in vivo methods...